首页 | 产品信息 | 技术研发 | 常规服务 | 订单下载 | 访客留言 | 联系我们  
 产品分类 
· 蛋白相关
·重组蛋白;
·蛋白提取试剂盒;
·蛋白定量试剂盒;
·蛋白纯化试剂;
·细胞培养添加蛋白因子;
·蛋白Marker
· 核酸相关
·吸附柱法核酸提取试剂盒;
·磁珠法核酸提取试剂盒
·免核酸提取样品保存液/核酸释放剂;
·核酸采集与保护套装;
·一次性病毒采样管套装;
·一步法新型冠状病毒荧光定量PCR试剂盒
·表达质粒
·一次性核酸胶体金试纸条
· 试剂盒相关
·ELISA 试剂盒;
·细胞凋亡检测试剂盒;
·细胞转染试剂;
·ECL高灵敏度化学发光试剂盒
· 抗体相关
·一抗;
·二抗;
·体外诊断(IVD)活性抗体;
·抗体纯化试剂
· CDMO服务
·细胞株开发;
·细胞培养工艺开发;
·蛋白纯化工艺开发;
·制剂工艺开发;
·中试放大生产;
·GMP生产服务
· 其他
·核酸清除剂
·灭菌注射用水
·荧光染料
 技术研发分类 
· 蛋白定制服务
· 抗体定制服务
· 试剂盒定制服务
· 课题项目服务
 常规服务分类 
· IF及IHC技术服务
· Western blot服务
· 蛋白纯化及标记服务
· 实时荧光定量PCR
产品信息 >> 蛋白相关 >> 重组蛋白;
Recombinant Human OPG

产品描述

概述

Osteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. OPG is a 401 a.a. basic glycoprotein which comprises 7 structural domains. It is either a 60 kDa monomer or a 120 kDa dimer linked by disulfide bridges. OPG acts as a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro and may also play a role in preventing arterial calcification. OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases. Mature human OPG shares 86 %, 87 %, 92 %, 92 % and 88 % amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively.

使用说明

This material is offered by Novin Biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

技术规格

Physical AppearanceSterile Filtered White lyophilized (freeze-dried) powder.
Purity> 95 % by SDS-PAGE and HPLC analyses.
SourceEscherichia coli.
Biological ActivityFully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL).
FormulationLyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB,150 mM NaCl, pH 6.0.
EndotoxinLess than 1 EU/ug of rHuOPG as determined by LAL method.
ReconstitutionWe recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 C. Further dilutions should be made in appropriate buffered solutions.
AA SequenceETFPPKYLHY DEETSHQLLC DKCPPGTYLK QHCTAKWKTV CAPCPDHYYT DSWHTSDECL YCSPVCKELQ YVKQECNRTH NRVCECKEGR YLEIEFCLKH RSCPPGFGVV QAGTPERNTV CKRCPDGFFS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK


上一篇:Recombinant Murine I    下一篇:Recombinant Human BD
关于我们   |   诚聘英才   |   信息发布   |   新品推荐   |   技术支持

     电话:400-832-8698    地址:北京怀柔雁栖开发区光织谷东区二号楼 

   备案/许可证编号京ICP备2020036913号

京ICP备2020036913号    技术支持:华大网络